This study entails enrolling participants that have been diagnosed with cancer to Olivia, a commercially available AI-enabled personal health platform developed by Tempus.
Olivia will serve as the primary interface for eConsent and enrollment into the registry. The platform will also help create a retrospective and prospective registry by working with over 1,000 healthcare systems to combine electronic health records (EHR) and Patient Reported Outcomes (PROs) in a single spot.
There may be sub-studies as an add-on to this parent protocol. The sub-studies will address specific goals of the targeted research activities and will usually include additional information specific to each research study.
Adults or children (all ages) with a pathologically confirmed diagnosis of cancer (solid tumor or hematologic malignancy) documented in the medical record; disease-specific cohorts may further define subtypes (e.g., stage, biomarker)
Receiving care in the United States and/or U.S. Territories
Participant (and/or legally authorized representative) is able and willing to provide electronic informed consent/permission and authorization via Olivia; with re-consent at age of eighteen if applicable
Willing to authorize medical record retrieval under HIPAA Right of Access and/or TEFCA IAS
Not Applicable
Receiving or have received care in the United States and/or U.S. Territories
Participant (and/or legally authorized representative) is able and willing to provide electronic informed consent/permission and authorization via the platform; with re-consent at age of eighteen if applicable
Legally authorized representative of participant who is deceased is able and willing to provide electronic informed consent/permission and authorization via the platform
All ages (adults and pediatrics), all indications (including solid tumors and hematologic malignancies, rare and genetic diseases, patients with suspected cancer or rare diseases, and healthy patients who have or may receive Tempus testing) and are receiving clinical care in the United States and/or U.S. Territories. Pathologically confirmed cancer diagnoses required for cohort-level analyses; biomarker-specific cohorts may be defined via the sub-study.
Cohort
Other
Not listed
Completeness and Yield of Multi-Modal Real-World Data Capture
Proportion of consented participants with successfully integrated and curated multimodal datasets (combining longitudinal electronic health record \[EHR\] data and genomic testing).
Click on the lead sponsor to view all of their trials.
Tempus AI
Lead sponsor
Blood Cancer United
Collaborator
